Factor V Leiden (Factor V G1691A), prothrombin gene mutation G20210A, and homozygous C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene are known to predispose venous thromboembolism (VTE). We present herein a rare case of a young woman heterozygous for these mutations and taking oral contraceptive pills for less than 2 months, diagnosed to have massive deep venous thrombosis and bilateral pulmonary embolism. The patient was managed for 10 days in the hospital and discharged home on oral anticoagulants. This case suggests that screening for these factors in people with family history of thrombosis and in relatives of patients with these mutations is highly recommended to prevent fatal consequences. In addition, a new guideline for treatment and prophylaxis with anticoagulant for these patients and others who are at risk of developing VTE (American College of Chest Physicians [ACCP] guidelines-Chest 2008) has been published recently. Our recommendation is to promote for the internationally published algorithms through their application, where necessary, to prevent any future thrombotic morbidity or mortality incidents.
Introduction
Venous thromboembolism (VTE) is considered nowadays the third leading cause of cardiovascular death in the United States, with deep venous thrombosis (DVT) affecting approximately 2 million persons yearly 1, 2 and with a pulmonary embolism (PE) incidence of 600 000 persons annually. 3 Venous thromboembolism is classified into DVT and PE. Venous thromboembolism incidence increases drastically in both males and females older than 60 years. 4 Although the risk factors of VTE in the elderly population are due to various inherited and/or acquired disorders, having VTE at an early age is mostly associated with the presence of inherited disorders.
Factor V Leiden (factor V G1691A) is a consequence of a single nucleotide substitution of arginine with glutamine at amino acid 506 in factor V gene, resulting in inability of activated protein C (APC) to cleave factor Va and VIIIa, prolonging the clotting time of plasma. [5] [6] [7] Although prothrombin gene mutation G20210A occurs at the base pair number 20 210 with guanine to adenine substitution, 8 mutation C677T in the methylenetetrahydrofolate reductase (MTHFR) gene is due to a substitution of a valine to an alanine, which leads to reduced activity of this enzyme. In case of homozygous state, MTHFR mutation can lead to hyperhomocysteinemia. 9 In Caucasians, factor V Leiden (factor V G1691A) is considered the most common genetic risk factor, followed by prothrombin gene mutation G20210A, with prevalence of 15% to 25% and 6% to 16% of unselected VTE patients, respectively. Additional risk factors are also present that can increase the risk of VTE, such as deficiencies in antithrombin III, protein C, or protein S, and homozygous mutation in C667T in the MTHFR gene. [10] [11] [12] [13] [14] [15] Venous thromboembolism is very rare in Asian and African populations. 14, 15 Many acquired risk factors are present nowadays that can precipitate VTE in predisposed young individuals as well as adults. These factors include surgery especially orthopedic, trauma, immobilization, age, obesity, smoking, malignancy, presence of a central venous catheter, pregnancy, acute infection, atherosclerotic diseases, use of oral contraceptive pills (OCP) or hormone replacement therapy (HRT), and some systemic diseases such as myeloproliferative diseases, hyperhomocysteinemia, antiphospholipid antibody syndrome, paroxysmal nocturnal hemoglobinuria, inflammatory bowel disease, and nephrotic syndrome. 16, 17 Case Report A 22-year-old woman, nonsmoker, previously healthy suffering from hursitism and was treated with OCP (estrogen pills) and spironolactone for less than 2 months. She presented to the emergency unit at the American University of Beirut Medical Center with 3 days' history of bilateral lower extremities pain, which became localized to the left-hand side only, prohibiting her from walking. She denied any trauma, history of malignancy, recent surgery, shortness of breath, or palpitation. She had no family history of VTE, PE, strokes, or recurrent abortions. In the emergency department, the patient was awake, in no distress, oriented to time and place with a heart rate of 110 beats/minutes, blood pressure of 110/70 mm Hg, respiratory rate of 18 breaths/minute, temperature of 36.7 C, and oxygen saturation of 99%. Her physical examination was unremarkable except for the lower extremities, which were swollen, with severe tenderness over the calf areas upon palpation, more on the left-hand side than on the right-hand side. The swollen area extends 35 cm below the knee and 50 cm in the thigh area. Duplex scan of the lower extremities revealed massive left ilio-femoro-popliteal vein thrombosis. On room air, arterial blood gas studies were as follows: PaO 2 ¼ 96, PaCO 2 ¼ 24, pH ¼ 7.52, B.D. (Base Deficit) ¼ À2, and HCO3 ¼ 20. Chest x-ray was normal. Computed tomography (CT) angiography of the chest showed bilateral lower lobe PE ( Figure 1A and 1B ). Electrocardiogram revealed right bundle branch block. Echocardiography revealed evidence of inferior vena cava (IVC) thrombosis without evidence of right ventricular strain. Peripheral blood count revealed white blood cell (WBC) of 14.2 Â 10 9 /L (83% neutrophils), hemoglobin of 11.5 g/dL, hematocrit of 33%, and platelets of 319 Â 10 9 /L. Her creatinine, blood urea nitrogen, sodium, potassium, chloride, carbon dioxide, magnesium, calcium, phosphate, and urinalysis were all normal. Direct and indirect coombs were negative. Work up of thrombophilia included protein C of 92.7%, protein S of 72%, homocysteine level of 12.9 mmol/ L, and antithrombin III of 81.3%. Upon genetic testing, the patient was found be heterozygous for factor V Leiden (G169A) mutation, factor II (G20210A) mutation, and MTHFR (C677T) mutation. Antiphospholipid antibody and anticardiolipin immunoglobulin M (IgM) and IgG were all negative. Finally, Janus kinase JAK2 V617F mutation done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was also not detected. In the emergency department, the patient was started on enoxaparin 1 mg/kg subcutaneously twice a day and transferred to intensive care unit (ICU). Catheter-directed lytic therapy could not be offered to her. She was then given TPA (Tissue Plasminogen Activator) thrombolytic therapy 60 mg via peripheral intravenous (IV) route as a drip over 2 hours, and then she was given IV heparin 4000 IU bolus once and started on continuous IV heparin at a rate of 1000 IU/h. During her stay, patient was doing well; her pain was controlled on morphine. She was discharged after 10 days on warfarin sodium and a weekly follow-up of her INR (International Normalizing Ratio). She presented to clinic 1 month later with recanalization of the popliteal and femoral veins.
Discussion
The prevalence of factor V Leiden in healthy people varies among populations. For the heterozygous form, prevalence is 2% to 10%. [18] [19] [20] Twenty percentage of patients having first thromboembolic episode are positive for heterozygous factor V Leiden. 21, 22 In Lebanon, the prevalence of factor V Leiden in heterozygous patients is 14% and is found in 40% of patients with VTE. 23 The second most common genetic factor leading to VTE is prothrombin gene mutation (G20210A). This autosomal dominant mutation is present in 1% to 3% in the general Caucasian population and in 9%of patients with VTE 21, 22, 24, 25 comparable to Lebanon with a prevalence of 1% to 3% in general population and 12.5% in patients with VTE. 23, 26 The prevalence of MTHFR heterozygous mutation varies from 2% to 54.5% depending on the ethnic group. In Lebanon, a recent study done by Sabbagh et al 9 showed that the carrier rate of MTHFR mutation is quiet high reaching 34.6% in the general population. In addition, it is documented that patients with heterozygous factor V Leiden have 3 to 10 increased relative risk (RR) of having VTE. 19, 20, 27 In combination with prothrombin gene mutation (G20210A), this RR increases 6-to 10-folds. 24 In the presence of other acquired factors for thrombosis, mainly use of OCP, the RR increases 30-to 40-folds in the presence of heterozygous factor V Leiden 27, 28 and to 16-folds in the presence of prothrombin gene mutation (G20210A). 25 Finally, homozygous MTHFR mutation that leads to hyperhomocysteinemia can increase the risk of thrombosis up to 2.5-folds. 20 As a conclusion, the presence of these genetic mutations in a woman potentiated by use of OCP would put her on highest risk of developing massive VTE or having recurrence in the future.
After diagnosing a patient with VTE and starting anticoagulant therapy, the question that arises is how long this patient should be put on treatment and what is the chance of recurrence of VTE if treatment is stopped especially when considering the occurrence of fatal PE. The risk of having fatal PE is expressed as an annual risk for fatal PE. Martinelli et al 29 have shown that patients with double heterozygous mutations for factor V Leiden and prothrombin gene mutation (G20210A) have 0.42% absolute annual risk (AAR) of a first episode of VTE, 0.19% and 0.13% AAR for factor V Leiden, and prothrombin gene mutation, respectively, compared to 0.0066% AAR of healthy population. In addition, many studies have shown an increased risk for recurrent VTE with patients' carriers of one or more genetic thrombotic risk factors. [30] [31] [32] [33] [34] [35] [36] In 1 study, 73.9% and 52.9% of patients having heterozygous mutations for factor V Leiden and prothrombin gene (G20210A) have recurrent thrombosis. 16 In a recent study done by Douketis et al, 37 2052 patients with VTE were followed up for 4.5 years. Results showed that AAR for fatal PE was 4% to 9% compared to 8% to 9% for AAR for anticoagulant-related bleeding. 38, 39 In addition, the annual risk for recurrence of VTE without continuing treatment is 10% 40 and annual risk for a major bleed while on anticoagulant therapy is 2%. 37 As a result, the annual risk of death from bleeding (0.16% to 0.18%) is lower than the annual risk of death from recurrent VTE (0.4% to 0.9%). Therefore, prophylactic anticoagulation for patients with previous VTE decreased their risk of having a major morbidity or mortality. However, because the AARs of death from either bleeding or recurrent thrombosis are very close, decision is still dependent on the treating physician.
We have presented a case of a young woman, diagnosed to be a carrier of heterozygous triple mutations, presenting with massive bilateral PE and massive lower extremity DVT while taking OCP medication. The coinheritance of these mutations together appears to put a person on high risk for thrombosis and recurrence, especially when an additional precipitating (acquired) factor is present. Moreover, the high prevalence of these mutations worldwide and mainly in Lebanon 9,23,26 in healthy as well as VTE patients would suggest lowering the threshold for screening for these mutations in persons with family history of thrombosis and in relatives of patients with these mutations to prevent fatal consequences. In addition, it is highly recommended to initiate and support national screening programs for thrombophilia mutations among these individuals. Recent studies have shown the benefit of prophylactic anticoagulation over bleeding from treatment. 37, 48 In addition, a new guideline for treatment and prophylaxis with anticoagulant for these patients and others who are at risk of developing VTE (ACCP guidelines-Chest 2008) has been published recently. [41] [42] [43] [44] [45] [46] [47] Our recommendation is to promote for the internationally published algorithms through their application, where necessary, to prevent any future thrombotic morbidity or mortality incidents.
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